METALYSE FOR INJECTION 10,000 U/VIAL [SIN12015P]

Product Info

METALYSE FOR INJECTION 10,000 U/VIAL

[SIN12015P]

4.1 Therapeutic indications

METALYSE is indicated for the thrombolytic treatment of acute myocardial infarction (AMI) with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.

4.2 Posology and method of administration

Posology

METALYSE should be administered as early as possible after symptom onset on the basis of body weight, with a maximum dose of 10,000 units (50 mg tenecteplase). The volume required to administer the correct dose can be calculated from the following scheme (table 1):

Adjunctive therapy:

Antithrombotic adjunctive therapy is recommended according to the current international guidelines for the management of patients with ST-elevation myocardial infarction.

For coronary intervention please refer to section 4.4 Special warnings and precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Method of administration

The reconstituted solution should be administered intravenously and is for immediate use.

The required dose should be administered as a single intravenous bolus over 5 to 10 seconds.

HANDLING INSTRUCTIONS

METALYSE should be reconstituted by adding the complete volume of water for injection from the pre-filled syringe to the vial containing the powder for injection.

1. Ensure that the appropriate vial size is chosen according to the body weight of the patient. (see section 4.2 Dosage and Administration)

2. Check that the cap of the vial is still intact.

3. Remove the flip-off cap from the vial.

4. Remove the tip-cap from the syringe. Then immediately screw the pre-filled syringe on the vial adapter and penetrate the vial stopper in the middle with the spike of the vial adapter.

5. Add the water for injection into the vial by pushing the syringe plunger down slowly to avoid foaming.

6. Keep the syringe attached to the vial adapter and reconstitute by swirling gently.

7. The reconstituted preparation is a colourless to pale yellow, clear solution. Only clear solution without particles should be used.

8. Directly before the solution is administered, invert the vial with the syringe still attached, so that the syringe is below the vial.

9. Transfer the appropriate volume of reconstituted solution of METALYSE into the syringe, based on the patient’s weight.

10. Unscrew the syringe from the vial adapter.

11. A pre-existing intravenous line, which has been used for administration of 0.9% sodium chloride solution only, may be used for administration of METALYSE. METALYSE should not be mixed with other drugs, neither in the same infusion-vial nor the same venous line (not even with heparin).

12. METALYSE should be administered to the patient, intravenously over 5 to 10 seconds. It should not be administered into a line containing dextrose as METALYSE is incompatible with dextrose solution.

13. The line should be flushed after METALYSE injection for proper delivery.

14. Any unused solution should be discarded.

15. Alternatively the reconstitution can be performed with a needle instead of the included vial adapter.

4.3 Contraindications

METALYSE is contraindicated in:

• patients with known hypersensitivity to the active substance tenecteplase, gentamicin (a trace residue from the manufacturing process) or to any of the excipients

• situations associated with a risk of bleeding such as:

  • significant bleeding disorder at present or within the past 6 months, known haemorrhagic diathesisany history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)

  • severe uncontrolled arterial hypertension (see section Special Warnings and Precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

  • severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis

  • active ulcerative gastro-intestinal disease

  • known arterial aneurysm and.or arterial/venous malformation

  • neoplasm with increased bleeding risk

  • bacterial endocarditis, pericarditis

  • acute pancreatitis

  • haemorrhagic stroke or stroke of unknown origin at any time.

  • patients receiving effective oral anticoagulant treatment (e.g. vitamin K antagonists with INR > 1.3) (please see section 4.4 Special Warnings and Precautions for use, subsection “Bleeding” – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information)

  • major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current AMI), recent trauma to the head or cranium